November 23, 2021 — Median Technologies announces new outstanding performance of its lung cancer screening (LCS) CADx1 to characterize malignant vs. benign lung nodules. New results specifically focus on the characterization of stage 1 lung cancer nodules, using Median's proprietary iBiopsy deep learning algorithm on low-dose chest computed tomography (LDCT).
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now